Semaglutide vs Tirzepatide: Which Wins, and What the Community Actually Switches To (2026)

For most people chasing maximum weight loss, tirzepatide is the stronger molecule: it beat semaglutide head-to-head in a direct trial (SURMOUNT-5) and posts higher average loss across studies. But "stronger on average" is not the same as "right for you," and semaglutide still wins on track record and cost. This page settles the question two ways at once: what the trials actually show, and what the ProtocolPlus community does when it has tried both.

Most "semaglutide vs tirzepatide" pages stop at a trial table. We add the signal no competitor has: among our users who logged both drugs, which direction people actually switch, how many run them in parallel, and how the day-to-day side effects compare in real reports. The trial evidence tells you what is possible; the community data tells you what people choose. For the full science on either molecule, we link up to its dedicated guide so this page stays a clean decision hub, and our roundup of the best peptides for weight loss sets both against every option people use.

Key Takeaways

• Head-to-head winner on weight loss: tirzepatide. In SURMOUNT-5, the first direct trial, tirzepatide reduced weight about 20.2% vs semaglutide's 13.7% over 72 weeks. Across separate trials the pattern holds: tirzepatide ~22.5% (SURMOUNT-1, 15 mg) vs semaglutide ~14.9% (STEP 1, 2.4 mg).
• Why tirzepatide pulls ahead: it is a dual GIP and GLP-1 receptor agonist, while semaglutide acts on GLP-1 alone. Two appetite-and-metabolism pathways instead of one.
• What our community does: among ProtocolPlus users tracking these two for weight loss, the split is roughly 45% semaglutide, 55% tirzepatide, and the net switch runs toward tirzepatide about 2.5 to 1 (34% of semaglutide users later moved to or added tirzepatide, vs 11% the other way). App data, a usage signal, not proof one is better for you.
• Semaglutide still wins on two things: the longest real-world and cardiovascular-outcomes track record, and cost (median $19 vs $56 per dose in our community data).
• Tolerability is close. Both are GI-dominant. In our reports nausea is near-identical (semaglutide 44% vs tirzepatide 42%); neither is clearly gentler.
• Both are FDA-approved: semaglutide as Wegovy (and Ozempic for type 2 diabetes), tirzepatide as Zepbound (and Mounjaro for diabetes). Compounded and research-grade versions are not the approved product.

Semaglutide vs tirzepatide at a glance

Here is the side-by-side before we go deep. Tirzepatide leads on raw efficacy; semaglutide leads on history and price. Everything below this table explains the why.

The table is the headline. The two places the answer genuinely flips are cost (semaglutide) and maximum average loss (tirzepatide), so most of the real decision comes down to which of those two you weight more.

What does the ProtocolPlus community actually do between the two?

This is the part no trial and no competitor page can give you: among users who have logged both, which way do people move? Trial data tells you what each drug can do in a controlled study; it cannot tell you what real people decide once they have lived with both, felt the side effects, and seen the monthly cost. That is the gap our first-party data fills. The short version is that the traffic is mostly one-way toward tirzepatide, but a meaningful minority go the other way for cost or tolerability, and a large group simply runs the strongest version they can get.

Three numbers carry the story, all from ProtocolPlus app data among the roughly 6,600 users tracking one of these two for weight loss:

• Adoption split: ~45% semaglutide, ~55% tirzepatide. Tirzepatide is the larger camp, but it is not a blowout. Within the full ~11,400-user weight-loss cohort, tirzepatide is 32% of all tracked compounds and semaglutide 26%.
• Co-tracking: ~16% (about 1,058 users) log both. These are people titrating across, comparing, or bridging supply gaps. Running both is common enough that "which one" is often really "which one first."
• Net switch favors tirzepatide ~2.5 to 1. About 34% of semaglutide users (roughly 1,008) later moved to or added tirzepatide, versus about 11% of tirzepatide users (roughly 401) who moved to or added semaglutide. The net flow, around 607 users, points to tirzepatide.

Which way people switch (and why it is not unanimous)

The reverse flow is small but real, and it tells you who semaglutide is still right for: people who hit their goal without needing tirzepatide's extra push, people who could not tolerate a dose step, and people for whom the price gap matters month after month. Switching is not a verdict that one drug is better. It is mostly people climbing toward the strongest tool they can access and afford.

The timing of the typical switch is itself informative. The most common pattern in the community is not "tried semaglutide briefly, bailed," but rather a switch after months on semaglutide, once weight loss flattens at or near the top dose and the scale stops moving. That plateau, not intolerance, is the usual trigger, and the destination is usually a mid-tier tirzepatide dose rather than the maximum, because the added GIP pathway often restarts progress without needing 15 mg right away. Clinicians generally move people across without a washout period, since both are weekly injectables in the same class. None of that is a protocol you should run on your own, but it explains why the switch data leans the way it does: people are chasing a stalled result, and the dual agonist tends to deliver one.

The efficacy case: what the trials actually show

The one-sentence answer: in the only head-to-head trial, tirzepatide produced clearly more weight loss than semaglutide, and separate trials agree. SURMOUNT-5 randomized 751 adults with obesity and no diabetes to one drug or the other for 72 weeks; tirzepatide reduced body weight about 20.2% versus about 13.7% for semaglutide, a treatment difference near 6.5 percentage points (roughly 22.8 kg vs 15.0 kg). That is a meaningful gap, not a rounding difference, and waist circumference moved further too (about 18.4 cm vs 13.0 cm).

The averages hide the more useful story, which is how many people reach each milestone. SURMOUNT-5 reported the share crossing each weight-loss threshold, and the gap widens as the bar rises. This is the breakdown most comparison pages leave out, and it is where the practical difference lives: if your target is a large reduction, tirzepatide roughly doubles your odds of getting there.

The separate trial programs point the same way. In STEP 1, once-weekly semaglutide 2.4 mg produced a mean reduction near 14.9% at 68 weeks (about 86% of patients lost at least 5% of body weight). In SURMOUNT-1, tirzepatide produced about 16.0%, 21.4%, and 22.5% at the 5, 10, and 15 mg doses on the efficacy estimand at 72 weeks (the more conservative treatment-regimen estimand was about 15.0%, 19.5%, and 20.9%). Cross-trial comparisons are imperfect because the populations, protocols, and time points differ, and you should treat STEP-versus-SURMOUNT math as suggestive only. That caveat is exactly why SURMOUNT-5 matters: same trial, same population, same clock, tirzepatide ahead.

One counter-intuitive detail from the head-to-head trial is worth flagging because it pushes against the "stronger drug, rougher ride" assumption: GI-related discontinuations were actually lower on tirzepatide (about 2.7%) than on semaglutide (about 5.6%). More weight loss did not come at the price of more people quitting for stomach issues in that study.

The mechanism explains the gap. Semaglutide activates the GLP-1 receptor, which blunts appetite, slows gastric emptying, and improves how the body handles glucose. Tirzepatide does all of that and adds a second agonist at the GIP receptor. GIP appears to complement GLP-1 in regulating appetite and energy handling, and in most people the combined effect is additive rather than redundant, which is the leading explanation for why the dual agonist consistently edges the single one. That is also why the two are not interchangeable doses of "the same thing": they are different molecules hitting a different number of targets. For the full pharmacology of each, see the semaglutide guide and the tirzepatide guide.

Same molecule, different jobs: the approval matrix

A point of constant confusion is that each drug has two brand names doing two different jobs, and the approved uses are diverging. The molecule is identical across a drug's brands; the indication, dose, and insurance coverage are not. This matters for the comparison because "which is better" sometimes really means "which is approved and covered for my situation."

The pattern: semaglutide currently has the broader set of approved benefits beyond weight (cardiovascular and liver), thanks to its longer trial history, while tirzepatide owns the sleep-apnea indication and the higher weight-loss numbers. If a second indication applies to you, it can decide the choice before efficacy even enters the picture. Coverage tracks the indication too: a plan may pay for Ozempic or Mounjaro with a diabetes diagnosis but decline Wegovy or Zepbound for obesity alone.

Averages are not your result: the variation problem

The one-sentence answer: the trial means hide enormous person-to-person spread, so the average gap between the two drugs can be smaller or larger than your personal difference would be. Both drugs have strong responders, weak responders, and non-responders, and you cannot know in advance which you are.

In every one of these trials, the distribution around the mean is wide. On tirzepatide some people lost over 30% of body weight while others lost almost nothing, and the same range exists on semaglutide. That has two implications for choosing. First, a strong semaglutide responder can out-lose a weak tirzepatide responder, so the population average does not dictate your individual outcome. Second, because you cannot predict your response, the common and sensible real-world approach is to start on one, give it a fair run at an effective dose, and judge by your own scale rather than by a trial chart. The community switch data is exactly this logic playing out at scale: people try, measure, and move only if their personal result stalls. Genetics, baseline metabolism, diet, sleep, and adherence all shape the outcome more than the choice between two closely related molecules.

Tolerability: closer than the efficacy gap suggests

The one-sentence answer: both are GI-dominant and broadly similar to tolerate, so tolerability rarely decides this matchup. People sometimes assume the stronger drug must be harder on the stomach, but the data does not support a clean split.

In our community reports the most common effects line up almost on top of each other: nausea (semaglutide 44% vs tirzepatide 42%), decreased appetite (40% vs 42%), diarrhea (30% vs 33%), constipation (24% vs 26%), and vomiting (22% vs 20%). These are self-reported community frequencies, not trial incidence and not proof of cause, but the pattern is clear: neither drug is the obviously gentler choice.

There is a subtle directionality that experienced users describe and our numbers hint at. Semaglutide complaints skew slightly toward nausea and constipation, while tirzepatide complaints skew a touch more toward diarrhea. The differences are small, but if you already know your gut, it can tip the call: someone prone to constipation may prefer to avoid stacking it, and someone who handles loose stools poorly may weigh that against tirzepatide. The far bigger lever for either drug is titration speed. Most severe GI episodes in both camps cluster around dose increases, which is why slow, patient escalation does more for tolerability than the choice between the two molecules. Notably, in the SURMOUNT-5 head-to-head, fewer people actually stopped tirzepatide for GI reasons than stopped semaglutide, so the stronger drug was not the harder one to stay on.

Both drugs share the same serious but rare warnings, including a boxed warning for thyroid C-cell tumors based on rodent data, plus pancreatitis and gallbladder risks. For the complete tolerability breakdown and red-flag list, read semaglutide side effects and tirzepatide side effects. This page does not duplicate them.

Cost: the one place semaglutide clearly wins

The one-sentence answer: in our community data semaglutide costs roughly a third of tirzepatide per dose, and over a year that gap is large enough to flip the decision for price-sensitive users. Cost is the single most common reason people switch back, or never switch up.

In ProtocolPlus cost figures, semaglutide runs about a median $19 per dose versus about $56 for tirzepatide, roughly a three-to-one difference. Spread across a year of weekly doses, that is the kind of gap that changes behavior, and it is the reason cost shows up again and again as the trigger for the smaller reverse switch from tirzepatide back to semaglutide. The efficacy edge is real, but it is not free, and the monthly difference is the lever most people actually feel.

Brand pricing without insurance is far higher for both, and the math is dominated by coverage rather than list price. Whether a plan pays often hinges on the indication on file: a type 2 diabetes diagnosis routes you to Ozempic or Mounjaro, which many plans cover, while obesity alone routes you to Wegovy or Zepbound, which are covered less consistently. Manufacturer savings programs, dose (you pay similarly per pen regardless of strength, so higher doses cost less per milligram), and the rise of compounded versions during shortages all move the real number a patient pays. We do not quote brand list prices here because they shift constantly and vary by pharmacy; treat the per-dose community figures as a directional signal, not a quote.

Speed, onset, and the first few weeks

The one-sentence answer: neither is a quick fix, and both follow the same slow-titration arc, so "which works faster" is mostly a myth. Appetite suppression often shows up within the first week or two on either drug, but visible weight change is a months-long process by design, because both are escalated gradually to protect tolerability.

The practical reality is that you spend the first one to two months at sub-therapeutic starting doses while your body adapts, on both drugs. Tirzepatide's larger eventual effect comes from reaching higher effective doses, not from acting faster early on. If anything, the honest expectation for either is steady, unglamorous progress over 6 to 18 months, with the steepest loss in the middle stretch once you are at an effective dose. People who switch for "speed" are usually really switching for a higher ceiling, which is a different thing.

What about retatrutide and the next generation?

A fair question when choosing today is whether to wait for something stronger. Retatrutide, a triple agonist (GIP, GLP-1, and glucagon), has posted the highest Phase 2 weight-loss figures of any of these compounds, and it is the destination some tirzepatide users are eyeing next. But it is investigational, not FDA-approved, and only available as research-grade supply, so it is not a like-for-like option against two approved drugs. For most people the real choice today is still semaglutide versus tirzepatide; retatrutide is a "later, maybe" rather than a "now." We keep the deep comparison on its own pages: see tirzepatide vs retatrutide and semaglutide vs retatrutide.

The editorial scorecard (the "why," not the verdict)

The fit-score radar below rates each drug 1 to 5 on six dimensions. With equal weighting the two essentially tie (77 vs 77): tirzepatide leads on effectiveness, semaglutide leads on cost, and they match on evidence, safety, access, and speed. That tie is the honest summary. The community usage data above, not this radar, is the headline signal, and your own priorities decide which dimension matters most.

Choose semaglutide if... / Choose tirzepatide if...

The decision rarely needs a coin flip. These two cards cover the great majority of cases.

Choose semaglutide if:

• You want the longest real-world and cardiovascular-outcomes track record (semaglutide has the larger evidence base, including the SELECT cardiovascular trial).
• Cost matters month to month. At roughly $19 vs $56 per dose in our data, semaglutide is the value pick.
• You are nausea-sensitive on dose steps and prefer a single-pathway, well-mapped titration.
• An oral option could matter (semaglutide exists as Rybelsus; tirzepatide is injectable only).

Choose tirzepatide if:

• Maximum average weight loss is the priority. It beat semaglutide head-to-head in SURMOUNT-5 and posts higher averages across trials.
• You have plateaued on semaglutide and want the added GIP pathway. This is the single most common move in our community data.
• You can absorb the higher per-dose cost for the bigger average result.
• You are starting fresh today and want the current efficacy leader.

The honest verdict

For most people whose only question is "which takes off more weight on average," tirzepatide is the answer, and the community votes with its feet: the net switch runs about 2.5 to 1 toward it. But semaglutide is not a runner-up so much as the better fit for a specific, large group, those who value its deeper track record, need an oral route, or feel the cost gap. If you are choosing today and price is not the deciding factor, tirzepatide is the stronger starting molecule. If cost or history matters most, semaglutide is a completely defensible choice that a quarter of our weight-loss community stays on by preference. Either way, the drug is a tool inside a clinician-supervised plan, not a decision to make from a comparison page alone.

To make it concrete, here is how the decision usually lands by situation:

• Most weight loss, cost not the deciding factor: tirzepatide.
• Tight monthly budget: semaglutide (about a third of the per-dose cost in our data).
• Plateaued on semaglutide near the top dose: switch to tirzepatide; this is the community's most common move.
• Have type 2 diabetes: either, as Ozempic or Mounjaro, guided by what your prescriber and plan favor.
• Have heart disease or liver disease (MASH): semaglutide currently carries those added approvals.
• Have obstructive sleep apnea with obesity: tirzepatide (Zepbound) is the one approved for it.
• Needles are a real barrier: semaglutide has an oral form (Rybelsus); tirzepatide does not.

For brand-specific angles, see Zepbound vs Wegovy and Mounjaro vs Ozempic. To weigh either against the next-generation triple agonist, see semaglutide vs retatrutide and tirzepatide vs retatrutide. To see where both rank against every option people use, see best peptides for weight loss.

Frequently Asked Questions

Sources

• Aronne LJ, Horn DB, le Roux CW, et al. "Tirzepatide as Compared with Semaglutide for the Treatment of Obesity" (SURMOUNT-5). New England Journal of Medicine, 2025. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
• Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (STEP 1). New England Journal of Medicine, 2021. DOI 10.1056/NEJMoa2032183. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1). New England Journal of Medicine, 2022. DOI 10.1056/NEJMoa2206038. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
• U.S. Food & Drug Administration. "FDA Approves New Medication for Chronic Weight Management" (Wegovy, semaglutide 2.4 mg). 2021. Retrieved 2026-06-18. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
• U.S. Food & Drug Administration. "FDA Approves New Medication for Chronic Weight Management" (Zepbound, tirzepatide). 2023. Retrieved 2026-06-18. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes" (SELECT). New England Journal of Medicine, 2023. DOI 10.1056/NEJMoa2307563. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
• ProtocolPlus. "Community head-to-head data: semaglutide vs tirzepatide" (head-to-head/semaglutide__tirzepatide.json). First-party app data, 2026. n ~ 6,612 users tracking one of the two for weight loss. Usage and switching signal, not a clinical efficacy verdict.